News

Vetter Pharma manufacturing site in Germany plans have been confirmed as the pharmaceutical service provider moves forward with building a new commercial production facility in the Saarland region of southwest Germany. The company said construction is scheduled to begin...

Drugmakers turn to AI as a practical way to reduce delays in clinical trials and regulatory submissions, even as artificial intelligence has yet to consistently deliver breakthrough drug molecules, industry executives said at the JP Morgan Healthcare Conference. Executives from...

Seamless Therapeutics has entered a global research collaboration and licensing agreement with Eli Lilly and Company under the Seamless Therapeutics Eli Lilly hearing loss collaboration, focused on developing programmable recombinase-based genetic medicines for hearing loss. The collaboration will unite Seamless...

AstraZeneca has agreed to license experimental obesity and metabolic disease drugs from China’s CSPC Pharmaceutical Group under the AstraZeneca CSPC weight-loss deal, with total potential payments reaching $18.5 billion. The agreement includes $1.2 billion paid upfront, with up to $17.3...

Malignant mesothelioma is one of oncology’s most challenging diagnoses. This aggressive cancer, primarily linked to asbestos exposure, has long represented a high-unmet-need indication where treatment options remained frustratingly limited. For decades, platinum-based chemotherapy served as the backbone of care,...

Clinical trials require carefully organized processes to ensure that medical research is conducted ethically, consistently, and in line with regulatory expectations. As studies grow in scale and complexity, many sponsors rely on external operational support to manage these requirements....

AstraZeneca has agreed to acquire Boston-based Modella AI as drugmakers continue to increase their use of artificial intelligence to accelerate research and development. Financial terms of the deal were not disclosed. Modella AI said its foundation models and AI agents...